arrow
L

Li Ren Kong

新加坡国立大学
H指数:27
被引数:3,542

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia

BCL-2依赖性是慢性淋巴细胞白血病对疗法反应的一个有利的预测性标志物。

2025-03-030
OA
Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)

II期开放标签随机研究:评估pembrolizumab联合或不联合bevacizumab治疗铂耐药复发/转移性鼻咽癌(R/M NPC)的疗效。

2024-09-011
PRE
Longitudinal probing of combinatorial immunotherapy (anti-VEGF/anti-PD1) response in advanced nasopharyngeal carcinoma, at single cell resolution

高级鼻咽癌中组合免疫治疗(anti-VEGF/anti-PD1)反应的纵向探查,在单细胞分辨率水平

2024-09-010
PRE
Insights from multi-omic modeling of neurodegeneration in xeroderma pigmentosum using an induced pluripotent stem cell system

使用诱导的多能干细胞系统对着色性干皮病神经变性进行多组建模的见解

2024-06-011
OA
Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)
2023-04-141
PRE
FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites
2023-01-0115
OAAI
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
2022-04-19228
OAAI
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
2020-10-1516
OAAI
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

通过诱导p53乙酰化靶向158位密码子p53-mutant癌症

2020-04-2928
OAAI
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
2020-03-2521
OAAI